Royalty Pharma
Royalty Pharma
RPRX
NASDAQ
32.70
USD
-0.46%
About
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies.
Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates.
Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 2.3M |
| Three Month Average Volume | 56.1M |
| High Low | |
| Fifty-Two Week High | 31.655 USD |
| Fifty-Two Week Low | 25.2 USD |
| Fifty-Two Week High Date | 27 Feb 2024 |
| Fifty-Two Week Low Date | 09 Jul 2024 |
| Price and Volume | |
| Current Price | 29.03 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -3.68% |
| Thirteen Week Relative Price Change | -1.04% |
| Twenty-Six Week Relative Price Change | -11.79% |
| Fifty-Two Week Relative Price Change | -22.31% |
| Year-to-Date Relative Price Change | -12.73% |
| Price Change | |
| One Day Price Change | -0.34% |
| Thirteen Week Price Change | 5.91% |
| Twenty-Six Week Price Change | -3.01% |
| Five Day Price Change | 2.98% |
| Fifty-Two Week Price Change | -2.65% |
| Year-to-Date Price Change | 3.35% |
| Month-to-Date Price Change | 3.05% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 14.61073 USD |
| Book Value Per Share (Most Recent Quarter) | 14.42164 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 14.61073 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 14.42164 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 1.60502 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 3.90538 USD |
| Revenue Per Share (Trailing Twelve Months) | 3.74032 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 0.8 USD |
| Dividend Per Share (Trailing Twelve Months) | 0.82 USD |
| Dividend Per Share (5 Year) | 0.508 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 2.53369 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 1.50411 USD |
| Normalized (Last Fiscal Year) | 2.53369 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 2.53537 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 1.50621 USD |
| Including Extraordinary Items (Last Fiscal Year) | 2.53369 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 1.50411 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.76197 USD |
| Cash Per Share (Most Recent Quarter) | 5.68568 USD |
| Cash Flow Per Share (Last Fiscal Year) | 2.81985 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 1.40354 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | 0.05529 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -2 |
| Cash Flow Revenue (Trailing Twelve Months) | 1 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 46.02% |
| Pretax Margin (Last Fiscal Year) | 72.20% |
| Pretax Margin (5 Year) | 67.80% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 63.37% |
| Operating Margin (Trailing Twelve Months) | 42.91% |
| Operating Margin (5 Year) | 68.57% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 72.20% |
| Net Profit Margin (Trailing Twelve Months) | 46.02% |
| Net Profit Margin (5 Year) | 67.80% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 2.69% |
| Tangible Book Value (5 Year) | 8.14% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -17.55% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -0.17% |
| Revenue Growth (3 Year) | 5.58% |
| Revenue Change (Trailing Twelve Months) | -5.24% |
| Revenue Per Share Growth | 5.31% |
| Revenue Growth (5 Year) | 3.52% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 50.99% |
| Total Debt (5 Year) | -1.21% |
| Dividends | |
| Dividend Growth (3 Year) | 38.67% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -55.20% |
| EPS Change (Trailing Twelve Months) | 167.73% |
| EPS Growth (3 Year) | 1.83% |
| EPS Growth (5 Year) | 24.31% |
| EBITDA | |
| EBITDA (5 Year) | 1.32% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -3.11% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 34 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 524 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 5.0B |
| Net Debt (Last Fiscal Year) | 4.9B |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 7 |
| Price to Sales (Trailing Twelve Months) | 8 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 19 |
| PE Normalized (Last Fiscal Year) | 11 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 18 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 358 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 11 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 19 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | 2.89% |
| Current Dividend Yield | 2.82% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 94 |
| Long Term Debt to Equity (Most Recent Quarter) | 117 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 31.58% |
| Payout Ratio (Trailing Twelve Months) | 54.64% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 8 |
| Current Ratio (Most Recent Quarter) | 9 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 514.0M |
| Free Cash Flow (Trailing Twelve Months) | 33.1M |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 94 |
| Total Debt to Equity (Most Recent Quarter) | 117 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 10.24% |
| Return on Assets (Trailing Twelve Months) | 5.92% |
| Return on Assets (5 Year) | 9.57% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 18.67% |
| Return on Equity (Trailing Twelve Months) | 10.55% |
| Return on Equity (5 Year) | 16.67% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 13.93% |
| Return on Investment (Trailing Twelve Months) | 7.77% |
| Return on Investment (5 Year) | 12.42% |